Invivyd, Inc. (NASDAQ:IVVD) Short Interest Update

Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) saw a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 8,260,000 shares, an increase of 24.0% from the March 15th total of 6,660,000 shares. Approximately 10.9% of the company's stock are sold short. Based on an average trading volume of 14,600,000 shares, the short-interest ratio is currently 0.6 days.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Jane Street Group LLC raised its position in Invivyd by 290.5% in the 4th quarter. Jane Street Group LLC now owns 117,432 shares of the company's stock worth $52,000 after buying an additional 87,358 shares during the last quarter. Barclays PLC raised its holdings in shares of Invivyd by 7.8% during the fourth quarter. Barclays PLC now owns 127,180 shares of the company's stock valued at $56,000 after purchasing an additional 9,207 shares during the last quarter. Renaissance Technologies LLC bought a new position in Invivyd during the fourth quarter valued at approximately $74,000. JPMorgan Chase & Co. boosted its holdings in Invivyd by 644.1% in the fourth quarter. JPMorgan Chase & Co. now owns 256,900 shares of the company's stock worth $114,000 after purchasing an additional 222,375 shares during the last quarter. Finally, Two Sigma Advisers LP grew its position in Invivyd by 1,276.5% in the 4th quarter. Two Sigma Advisers LP now owns 304,200 shares of the company's stock worth $135,000 after purchasing an additional 282,100 shares during the period. 70.36% of the stock is owned by institutional investors.

Invivyd Stock Down 2.8 %

Invivyd stock traded down $0.02 during trading hours on Friday, hitting $0.65. The stock had a trading volume of 807,216 shares, compared to its average volume of 4,284,438. The stock's 50-day moving average price is $0.78 and its 200-day moving average price is $0.78. The stock has a market capitalization of $77.96 million, a P/E ratio of -0.33 and a beta of 0.41. Invivyd has a 12-month low of $0.35 and a 12-month high of $2.74.

Invivyd (NASDAQ:IVVD - Get Free Report) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.10. The firm had revenue of $13.80 million during the quarter, compared to analysts' expectations of $13.57 million. On average, research analysts expect that Invivyd will post -1.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. D. Boral Capital reiterated a "buy" rating and set a $9.00 target price on shares of Invivyd in a report on Thursday, March 20th. HC Wainwright reiterated a "buy" rating and set a $10.00 price objective on shares of Invivyd in a research note on Wednesday, March 26th.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.